Leptoprol

Leuprorelin, the active ingredient in Leptoprol, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a subcutaneous injection for subcutaneous use. It is employed in the management of hormone‑dependent cancers and benign gynecological conditions in adult patients and is indicated for several endocrine‑related disorders.

GNH USA supplies Leptoprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions.

Leptoprol (leuprorelin) acts on the gonadotropin‑releasing hormone pathway to suppress sex hormone production in several hormone‑dependent conditions.

- Prostate cancer: reduces testosterone levels to slow tumor growth. - Endometriosis: lowers estrogen production, alleviating pelvic pain and lesion progression. - Uterine fibroids: diminishes estrogen‑driven fibroid size and related bleeding. - Precocious puberty: suppresses early activation of the hypothalamic‑pituitary‑gonadal axis. - Breast cancer: decreases estrogen exposure in hormone‑sensitive tumors.

Leuprorelin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes. - Injection site pain or erythema. - Headache. - Fatigue.

Serious or Rare Side Effects: - Loss of bone mineral density leading to osteoporosis. - Severe allergic reaction (anaphylaxis).

Before initiating therapy, clinicians should consider several safety measures.

- Hormone monitoring: regularly assess serum testosterone or estradiol levels to confirm suppression. - Bone health: evaluate bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular risk: screen for pre‑existing heart disease before initiating therapy. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential. - Drug interactions: review concomitant hormonal therapies that may alter efficacy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Combined estrogen or testosterone therapy: may counteract hormone suppression. - Anticoagulants: increased risk of bleeding at injection sites.

Moderate Interactions (Monitor Closely): - Bisphosphonates or denosumab: monitor bone turnover markers. - Antidepressants (SSRIs): may exacerbate mood changes. - Live vaccines: potential reduced immunogenic response.